MedTrace Logo

Safety Study of AZD5672 in Renally Impaired Subjects

NCT00715702 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2009-04-29

No results posted yet for this study

Summary

The purpose of the study is to investigate the pharmacokinetics of a single dose of AZD5672 in patients with renal impairment by comparing with healthy volunteers

Conditions

  • Renal Impairment

Interventions

DRUG

AZD5672

100 mg oral single dose

Sponsors & Collaborators

Principal Investigators

  • Rod Hepburn · AstraZeneca R&D, Charnwood, UK

  • Angelika Weil · APEX GmbH

Study Design

Allocation
NON_RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-07-31
Primary Completion
2009-02-28
Completion
2009-02-28

Countries

  • Germany

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00715702 on ClinicalTrials.gov